All In Biotech

Drug Trial Radar · NCT03535298

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Jan 3, 2019

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
The Cleveland ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Nottingham
First posted
May 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • Early Highly Effective Therapies GroupDrug

    Highly Effective MS Therapy group of medications

  • Escalation Therapies GroupDrug

    Escalation MS Therapy group of medications

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Brain volume loss, baseline to month 36Time frame: Baseline to 36 months
  2. EDSS+, month 48 to month 108Time frame: 48 months to 108 months

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Colorado-Anschutz Medical Campus

    Aurora, Colorado

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Cleveland Clinic Lou Ruvo Center for Brain Health

    Las Vegas, Nevada

  • University of Buffalo

    Buffalo, New York

  • University Rochester Medical Center

    Rochester, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio Health

    Columbus, Ohio

  • UT-Austin

    Austin, Texas

  • Baylor College of Medicine, Houston

    Houston, Texas

  • UTHealth-Houston

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • University of Wisconsin-Madison

    Madison, Wisconsin

  • Nottingham University Hospitals NHS Trust, Queens Medical Centre

    Nottingham, United Kingdom

  • University Hospitals Coventry and Warwickshire

    Coventry, England, United Kingdom

  • The Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary

    Leeds, England, United Kingdom

  • University Hospitals Leicester

    Leicester, England, United Kingdom

  • Imperial College Healthcare NHS Trust, Charing Cross Hospital

    London, England, United Kingdom

  • University College London Hospitals NHS Foundation Trust, University College Hospital

    London, England, United Kingdom

  • Salford Royal NHS Foundation Trust, Salford Hospital

    Manchester, England, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital

    Oxford, England, United Kingdom

  • University Hospitals Plymouth NHS Trust, Derriford Hospital

    Plymouth, England, United Kingdom

  • Sheffield Teaching Hospitals

    Sheffield, England, United Kingdom

  • University Hospitals of North Midlands

    Stoke, England, United Kingdom

  • Royal Infirmary of Edinburgh

    Edinburgh, Scotland, United Kingdom

  • Cardiff and Vale University Local Health Board, University Hospital of Wales

    Cardiff, Wales, United Kingdom

  • Aneurin Bevan Local Health Board Headquarters, Royal Gwent Hospital

    Newport, Wales, United Kingdom

  • Swansea Bay University Local Health Board, Morriston Hospital

    Swansea, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.